Aliskiren combined with losartan in type 2 diabetes and nephropathy by Parving Hans-Henrik, Persson Frederik, Lewis Julia B, Lewis Edmund J, Hollenberg Norman K, AVOID Study Investigators in The New England journal of medicine (2008). PubMed

Abstract

Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin-angiotensin-aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy.

[ hide abstract ]

Discussed In Paper